Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
2024年7月15日 - 2:00PM
Ad Hoc Announcement Pursuant to Art. 53
LR
Geneva, Switzerland, July 15,
2024 - Addex Therapeutics (SIX: ADXN and
Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused
on developing a portfolio of novel small molecule allosteric
modulators for neurological disorders, announced today that
positive results from the Company’s novel gamma-aminobutyric acid
sub-type B receptor (GABAB) positive allosteric modulator (PAM)
chronic cough program will be presented during the Thirteenth
London International Cough Symposium (13th LICS) on July 19 and an
abstract is available to conference participants on-line from
today.
In models of chronic cough in guinea pigs, the
candidate GABAB PAM, significantly and dose-dependently reduced
citric acid-induced cough frequency (minimal efficacious dose 1
mg/kg), increased cough latency and showed no signs of tolerance
after sub-chronic treatment. In comparison with the GABAB agonist
baclofen, the selective GABAB PAM showed a wider safety margin,
separating its minimal efficacious dose from the dose linked to
side-effects. Baclofen exhibits antitussive properties, but its
broad clinical use is hampered by its short half-life and central
nervous system side effects including sedation.
“To our knowledge, this is the first time a
highly selective GABAB PAM has demonstrated antitussive activity in
animal models of cough,” said Dr. Mikhail Kalinichev, Head of
Translational Science at Addex, who will be presenting the data.
“We believe that a GABAB PAM with antitussive efficacy, combined
with reduced centrally-mediated side-effects and improved
tolerability in comparison to baclofen, has the potential to become
a best-in-class treatment for chronic cough.”
About GABAB activation and
cough: The main inhibitory neurotransmitter GABA activates
ionotropic (GABAA) and metabotropic (GABAB) types of receptors.
GABAB receptors are widely expressed on airways and in the central
and peripheral components of the cough neural circuit. Activating
GABAB receptors to treat chronic cough has been clinically
validated with baclofen, a selective GABAB agonist, that binds the
receptor within the orthosteric GABA binding site. Baclofen is used
off-label to treat chronic cough patients, but its wider use is
limited due to serious side effects, short half-life and gradual
loss of efficacy during chronic treatment. Targeting an allosteric
site of the receptor is expected to provide many advantages,
including higher selectivity, better tolerability and lack of
tolerance compared to an orthosteric compound.
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing a portfolio of novel small molecule allosteric
modulators for neurological disorders. Addex’s lead drug candidate,
ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals Inc., has completed
several Phase 2 clinical studies, including in schizophrenia,
anxious depression and, more recently, one in epilepsy patients.
The Company’s second clinical program, dipraglurant (mGlu5 negative
allosteric modulator or NAM), is under evaluation for future
development in dyskinesia associated with Parkinson’s disease and
post-stroke/TBI recovery. In Addex’s GABAB PAM partnership with
Indivior, multiple drug candidates are advancing through clinical
candidate selection for substance use disorder. Under the agreement
with Indivior, Addex is advancing an independent GABAB PAM program
for chronic cough. Addex also holds a 20% share in a private
company, Neurosterix LLC which is advancing a portfolio of
allosteric modulator programs including M4PAM for schizophrenia,
mGlu7NAM for undisclosed psychiatric indications and mGlu2NAM for
mild neurocognitive disorders. Addex shares are listed on the SIX
Swiss Exchange and American Depositary Shares representing its
shares are listed on the NASDAQ Capital Market, and trade under the
ticker symbol “ADXN” on each exchange. For more information, visit
www.addextherapeutics.com
Contacts:
Tim DyerChief
Executive OfficerTelephone: +41 22 884 15 55
PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2023, as filed with the SEC on April 18, 2024,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
過去 株価チャート
から 7 2024 まで 8 2024
Addex Therapeutics (NASDAQ:ADXN)
過去 株価チャート
から 8 2023 まで 8 2024